A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Study acronym: Celestimo
StatusActive, Not Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 64 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 112 to 111
    • Eligibility criteria expanded, about 40 words
  2. Primary completion date changed from estimate of Jun 30, 2026 to Jun 3, 2026v63
  3. Primary completion pushed from May 31, 2026 to Jun 30, 2026
    • Study sites revised (112)
    v62
  4. Primary completion date: Jan 12, 2026 to May 31, 2026v61
  5. Re-verified, no change to tracked fieldsv60
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 1 of 112 sitesv59
  2. Study sites: 113 to 112v58
  3. Study sites: 116 to 113
    • Primary completion date: Sep 29, 2025 to Jan 12, 2026
    v57
  4. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 474 to confirmed 478
    • Study sites: 153 to 116
    v56
  5. Primary completion date: Aug 25, 2025 to Sep 29, 2025
    • Study completion date: May 1, 2029 to Dec 31, 2029
    v55
  6. Secondary endpoints: details revised at 13 of 13 entriesv54
  7. Secondary endpoints revised (13)
    • Study sites revised (153)
    v53
  8. Re-verified, no change to tracked fieldsv52
  9. Study sites: 151 to 153v51
  10. Site details revised at 4 of 151 sitesv50
  11. Site details revised at 5 of 151 sitesv49
  12. Study sites: 148 to 151v48
  13. Site details revised at 3 of 148 sitesv47
  14. Study sites: 146 to 148v46
  15. Site details revised at 19 of 146 sitesv45
  16. Site details revised at 10 of 146 sitesv44
  17. Site details revised at 8 of 146 sitesv43
  18. Study sites: 145 to 146v42
  19. Site details revised at 14 of 145 sitesv41
  20. Site details revised at 7 of 145 sitesv40
  21. Enrollment target: 400 to 474
    • Site details revised at 4 of 145 sites
    • Study arms: 2 to 3
    v39
  22. Site details revised at 12 of 145 sitesv38
  23. Study sites: 144 to 145v37
  24. Site details revised at 8 of 144 sitesv36
  25. Study sites: 143 to 144v35
  26. Site details revised at 27 of 143 sitesv34
  27. Site details revised at 46 of 143 sitesv33
  28. Site details revised at 37 of 143 sitesv32
  29. Study sites: 138 to 143v31
  30. Site details revised at 12 of 138 sitesv30
  31. Study sites: 132 to 138v29
  32. Study sites: 131 to 132v28
  33. Primary completion date: May 1, 2029 to Aug 25, 2025
    • Study sites: 126 to 131
    v27
  34. Study sites: 125 to 126v26
  35. Study sites: 122 to 125v25
  36. Study sites: 116 to 122v24
  37. Study sites: 111 to 116v23
  38. Study sites: 109 to 111v22
  39. Study sites: 105 to 109v21
  40. Study sites: 95 to 105v20
  41. Study sites: 90 to 95v19
  42. Study sites: 89 to 90v18
  43. Study sites: 71 to 89v17
  44. Study sites: 55 to 71v16
  45. Study sites: 37 to 55v15
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
Trial Details
NCT Number NCT04712097
Lead Sponsor Hoffmann-La Roche
Conditions
(from sponsor)		 Relapsed or Refractory Follicular Lymphoma
Related terms Lymphoma, Follicular, Recurrence
Enrollment 478 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov